Stocks Health care PLYX
NASDAQ · Health carePolaryx Therapeutics, Inc. (PLYX)
It posted a net loss of $9M. At June 30, 2026 it held $11.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Polaryx Therapeutics, Inc.
- Net worth
- Polaryx Therapeutics, Inc. has a market value (market cap) of $96.7M at the latest share price, and shareholders' equity of $10.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $3.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Polaryx Therapeutics, Inc.'s next report was expected around October 23, 2026 and is not on file with the SEC yet.
What Polaryx Therapeutics, Inc. does
Polaryx Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PLYX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$9M | -$0.20 | n/a |
| 2025 | n/a | -$30.4M | -$0.89 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Polaryx Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 1, 2026
- August 13, 2026
- July 28, 2026
- July 28, 2026Additional proxy material DEFA14A
- July 28, 2026Proxy statement DEF 14A
- July 24, 2026
- July 21, 2026
- July 17, 2026
- May 28, 2026
Insider trades
What the people running Polaryx Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Yang Alex Keun MoChief Executive Officer, Director, 10% owner | Boughtindirect | 88,453 | $360K |
| February 18, 2026 | Landis G. MichaelChief Financial Officer, Director | Bought | 2,867 | $8K |
Who owns PLYX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alex Keun Mo Yang13D, may seek influence with 3 related filers | 48% | February 5, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 24,461,474 shares in total, about $47.5M at the last price.
| Holder | Shares |
|---|---|
| Yang Alex Keun MoChief Executive Officer, Director, 10% owner | 24,233,24924,233,249 held indirectly |
| Landis G. MichaelChief Financial Officer, Director | 228,225 |
Questions about PLYX
What does Polaryx Therapeutics, Inc. do?
Polaryx Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as PLYX. Its shares trade on NASDAQ under the ticker PLYX.
What is Polaryx Therapeutics, Inc.'s net worth?
Polaryx Therapeutics, Inc. has a market value (market cap) of $96.7M at the latest share price, and shareholders' equity of $10.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Polaryx Therapeutics, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $9M.
When did Polaryx Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 14, 2026.
When is Polaryx Therapeutics, Inc.'s next earnings report?
Polaryx Therapeutics, Inc.'s next report was expected around October 23, 2026 and is not on file with the SEC yet.
Similar companies
Compare PLYX with
Follow PLYX
Get an email when Polaryx Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Polaryx Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.